Abbott Labs Q4 Earnings Miss on Revenue as Nutrition Sales Decline
Abbott Laboratories shares tumbled 8% after reporting fourth-quarter revenue of $11.5 billion, falling short of Wall Street's $11.8 billion estimate. While adjusted EPS met expectations at $1.50, weak performance in the nutrition segment dragged down results.
The company's medical devices segment showed strength with 12% growth, and established pharmaceuticals ROSE 9%. However, nutrition sales plummeted 8.9% as price increases dampened consumer demand amid persistent commodity cost pressures.
Abbott maintained its 2026 guidance, projecting adjusted EPS between $5.55-$5.80 with organic sales growth of 6.5-7.5%. The $21 billion Exact Sciences acquisition remains on track for Q2 2026 closing.